We’re starting off the year strong here at MapLight and would like to give a warm welcome our new hire: Mark Black - Executive Director, Medical Writing. Welcome to MapLight!

This month’s #employeespotlight is on Brandon Abbs, who’s at the forefront of our #autismresearch here at MapLight. Thank you for all that you do, Brandon! #LifeAtMapLight

Our partners at SARRC are opening a new school campus in Mesa, AZ, for children with #autism aged 15 months to 5 years old! This is a big step forward in #autismeducation and support. Learn more: autismcenter.org/mesa

We’re recruiting for our IRIS Phase 2 trial of ML-004, targeting core social communication deficits in #autismspectrumdisorder. Learn more. maplightrx.com/iris-trial/

We are #hiring professionals in clinical operations, pharmacology, and CMC to join our team. Ready to make a difference with #CNSDisorders? Apply today. job-boards.greenhouse.io/map…

The MapLight team surpassed 100 employees in 2024! Thank you for your incredible support, helping us grow and succeed. Excited for what 2025 holds. #YearInReview #HappyNewYear

#HappyHolidays from all of us at MapLight! To all of our science lovers out there, can you identify the background of our festive graphic? Respond w/ your guess.

Meet Jim – a leader in our computational science efforts to design targeted therapeutics for brain disorders. Thank you for all you do for MapLight, Jim! #EmployeeSpotlight #LifeAtMapLight

As we close out the year, we’d like to welcome a new team member. Join us in welcoming Kimberly Randall, Accounts Payable Manager. #WelcomeToMapLight #LifeAtMapLight

Thank you to all who joined us for our poster presentation at the #ACNP2024 meeting. This prestigious forum brings together world-leading scientists to exchange knowledge about the understanding and treatment of brain disorders.

Team members from across the U.S. came together last week to celebrate MapLight’s ‘24 successes and look ahead. We also made hygiene kits for Samaritan House in SF to give back to our community. #LifeAtMapLight

Today, we recognize the need for inclusive treatments and scientific research in honor of #IDPWD. As an organization, we embrace inclusivity and the differences of all people.

Today, we shared Phase 1 results for ML-007/PAC, a novel M1/M4 muscarinic agonist in development for the treatment of #schizophrenia & #Alzheimersdiseasepsychosis. Read more here: maplightrx.com/maplight-ther…

To kick off the holidays, we’re grateful for our dedicated team and everyone working to improve the lives of those affected by #braindisorders. Wishing you a safe and joyful season.

Meet Alice Hong, one of our dedicated Research Scientists! What does she find exhilarating about coming to work each day? Read her quote to find out! #EmployeeFeature #EmployeeAppreciation #LifeAtMapLight

We’re excited to present a poster at the upcoming #ACNP2024, 12/8-12/11! Mark your calendars and we hope to see you there.

We’re attending two key investor conferences this November— Stifel in NYC on 11/18 and Jeffries in London, 11/19-21.  #InvestorConferences #HealthcareInnovation

We had a great time presenting at the #NEICongress in snowy Colorado Springs! Our poster highlighted ML-007’s effects on psychosis & cognition in preclinical models of #schizophrenia & #Alzheimers. Thanks to everyone who stopped by to say hi! #NEI2024

This #VeteransDay, we honor those who have served our country and acknowledge the critical need for mental health support for veterans. We’re dedicated to advancing treatments to improve #mentalhealth outcomes.